Wegovy for heart disease: the SELECT trial and the cardiovascular indication (2026)

Why this was a milestone

For years, weight-loss drugs were judged on how much weight they took off. SELECT asked a harder question: does the drug prevent the outcomes people actually fear — heart attacks, strokes, and cardiovascular death? On March 8, 2024, the FDA approved Wegovy to reduce those risks in adults with established cardiovascular disease and obesity or overweight, making it the first weight-management medication with a cardiovascular-benefit indication [2].

That is a categorically stronger claim than weight loss, and it rests on a categorically larger and longer trial. A weight-loss approval needs to show the scale moves; an outcomes approval needs to show that real cardiovascular events — the ones that put people in the hospital or worse — happen less often. SELECT is what let semaglutide clear that higher bar [1].

How SELECT was designed

SELECT was a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial. It enrolled 17,604 patients aged 45 or older who had preexisting cardiovascular disease and a body-mass index of 27 or greater, but no history of diabetes. They were assigned 1:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo [1].

The primary endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke — the standard 'major adverse cardiovascular events' (MACE) measure — in a time-to-first-event analysis. Excluding people with diabetes was deliberate: it isolated the cardiovascular effect in the overweight-and-obese population, rather than in the diabetes population where GLP-1 heart benefits were already known. 'Event-driven' means the trial ran until enough events accrued to give a statistically reliable answer, which is why it lasted years rather than a fixed number of weeks [1].

What it found

Over a mean exposure of about 34 months and mean follow-up of 39.8 months, a primary cardiovascular event occurred in 569 of 8,803 patients (6.5%) in the semaglutide group versus 701 of 8,801 (8.0%) in the placebo group. The hazard ratio was 0.80 (95% CI, 0.72 to 0.90; P<0.001) — a 20% relative reduction in major cardiovascular events [1].

The trade-off was tolerability, not a safety alarm: adverse events leading to permanent discontinuation occurred in 16.6% of the semaglutide group versus 8.2% with placebo, driven mainly by the familiar gastrointestinal effects of the drug class. In other words, more people stopped the drug for nausea-type side effects, but the trial did not surface a dangerous new safety signal [1].

How big is a 20% reduction, in real terms?

A '20% relative reduction' sounds dramatic, and it is meaningful, but it helps to see the absolute numbers too. The event rate fell from 8.0% to 6.5% — a 1.5 percentage-point absolute reduction over about 3.3 years [1]. Put another way, treating a large group of high-risk patients for that period prevents a meaningful number of heart attacks, strokes, and cardiovascular deaths that would otherwise have occurred.

Both framings are true and both matter. The relative reduction (20%) tells you how much the drug shifts your odds; the absolute reduction (1.5 points) tells you how common the benefit is at the population level. For an individual with established heart disease, a one-fifth cut in the chance of a major cardiac event is a benefit on the same scale as some long-established cardiovascular medications — which is exactly why the approval was significant.

Is it the weight loss, or something more?

Participants lost weight, and weight loss on its own improves blood pressure, blood sugar, and cholesterol — all of which help the heart. But many researchers think weight loss is only part of the story, because the cardiovascular benefit appeared larger and to emerge earlier than the degree of weight loss alone would easily predict [1].

The leading additional explanations are semaglutide's effects beyond the scale: lowering inflammation (a driver of the artery disease behind heart attacks), direct actions on blood vessels and the heart, and improvements in metabolic markers. The mechanism is still being studied. For a patient, the practical point is reassuring: the benefit was measured as actual prevented events, so it holds regardless of which pathway ultimately explains it.

What it means for coverage and care

The practical downstream effect is access. Medicare Part D generally cannot pay for drugs used only for weight loss, which had put branded GLP-1s out of reach for many older adults. A cardiovascular-benefit indication is different: after the 2024 approval, plans gained a basis to cover Wegovy for cardiovascular risk reduction in eligible patients with established heart disease, and in 2024 Medicare issued guidance allowing Part D plans to cover it for that indication. Commercial insurers often follow the same logic — coverage attaches to an approved medical indication [2].

If you have established cardiovascular disease and are overweight or have obesity, this indication may be the difference between 'not covered' and 'covered with prior authorization.' It is worth raising with both your cardiologist and your prescriber, and worth checking your specific plan's criteria rather than assuming either way, since documentation of the qualifying heart disease is usually required.

Who exactly qualifies, and what to ask

The SELECT population — and the FDA indication that followed — is specific: adults with established cardiovascular disease (such as a prior heart attack, stroke, or peripheral artery disease) plus overweight or obesity (BMI 27 or higher), without a diagnosis of diabetes. That is narrower than 'anyone who wants to lose weight' and broader than 'diabetics only.' If you have had a cardiac event and carry extra weight, you may fit; if you are using Wegovy purely for weight loss without heart disease, the cardiovascular indication (and its coverage pathway) doesn't apply to you [1][2].

Bring it to the clinician who manages your heart. The useful questions are whether your history meets the cardiovascular-disease criterion, whether the CV indication changes your insurance coverage, and how semaglutide fits alongside the statins, blood-pressure drugs, and antiplatelet medications you may already take — it adds to, rather than replaces, standard cardiovascular care.

The bottom line

SELECT moved semaglutide from a weight-loss drug to a cardiovascular risk-reduction drug for a specific group: adults with established heart disease and overweight or obesity, without diabetes. A 20% relative (1.5 percentage-point absolute) reduction in heart attacks, strokes, and cardiovascular death is a large, outcome-level benefit — and the indication it produced can also unlock coverage that weight loss alone did not. Talk to a clinician about whether you fit the population the trial actually studied, and treat it as part of your cardiovascular care, not a standalone weight tool.